Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
- Acquisition of a technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization;
- This new technology will round out Guerbet's Interventional Imaging solutions and create synergies with the Accurate range of anti-reflux microcatheters.
Villepinte (France), April 26, 2018 (18:00 CEST) - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announced today that it has signed an agreement to acquire a laboratory-stage technology developed by Occlugel, a French company specialized in the R&D of microspheres used in embolization.
This acquisition is line with the GEAR 2023 strategic plan, and is one of two acquisitions planned by the end of this financial year.
"We are very pleased to integrate this new microsphere technology into our Interventional Imaging R&D program", said Claire Corot, Research, Innovation & Business Development VP.
Under the terms of the agreement and in exchange for the acquisition of this technology, Guerbet has made an initial payment of €3 million, with additional payments conditional on completing the technology transfer and achieving regulatory objectives.
A complementary technology for Interventional Imaging
The technology will be used in several ranges of microspheres for vascular embolization of benign tumors, for example uterine fibroma and prostate adenoma, and for vascular chemoembolization of malignant tumors, including in some liver, lung and kidney cancers.
This technology will complete the existing range of Guerbet's Interventional Imaging solutions, and above all create strong synergies with the Accurate range of anti-reflux microcatheters, acquired recently by Guerbet.
About Guerbet
Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 7% of revenue dedicated to R&D and more than 200 employees distributed amongst its three centers in France and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €807 million in revenue in 2017. For more information about Guerbet, please visit www.guerbet.com
Media Relations
| Guerbet Global Alize RP Caroline Carmagnol and Wendy Rigal +33 (0)1 44 54 36 66 / +33 (0)6 48 82 18 94 [email protected] | |
Attachment
